ERBB2 and breast carcinoma: We further analyzed the changes in antibody titers in patients with different molecular subtypes of breast cancer, including 18 cases of the HR+/Her2+ subtype, 48 cases of the HR+/Her2– subtype, 18 cases of the HR–/Her2+ subtype, and 10 cases of the HR–/Her2– subtype.